Catherine Lee, J.D., is the General Counsel at Neogene Therapeutics. She joined Neogene in 2022 with over 20 years of experience, advising public and privately held companies in biotechnology and other industries. Before joining Neogene, Catherine served as the Executive Vice President, General Counsel and Corporate Secretary of Metacrine, Inc., where she provided executive oversight and counsel for the business, including on corporate governance and compliance matters, financing and investor related matters, business and corporate development, IP portfolio management and research and clinical programs. Prior to Metacrine, she served as the SVP, General Counsel of Omniome, Inc. Previously, she was the SVP, General Counsel and Corporate Secretary of Senomyx, Inc. until its acquisition by Firmenich S.A. Before joining the biotechnology industry, Catherine advised Outdoor Channel Holdings, Inc., serving most recently as its EVP, General Counsel and Corporate Secretary. Prior to that, Catherine held legal positions of increasing responsibility with Sempra Energy, where she last served as Corporate Secretary and Counsel. She began her career as an associate at Brobeck, Phleger & Harrison, LLP and at Morrison & Foerster, LLP. Catherine received her J.D. from the University of Illinois, College of Law, and her B.A. in International Relations and Economics from American University, School of International Service.